Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Axonics Modulation Technologies Inc (AXNX) Insider Trading Activity
Healthcare • Medical Devices • 797 employees
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Total Value
-$46,611,855.00
Total Shares
-656,505
Average Trade Value
-$3,585,527.31
Most Active Insider
Cohen Raymond W
Total Activity: $20,783,901
Largest Single Transaction
$20,783,901
by Cohen Raymond W on Nov 15, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Nov 15, 2024 | 17,861 | $1,268,131 | 0 | Sale to Issuer | ||
Chief Medical Officer
|
Nov 15, 2024 | 34,428 | $2,444,388 | 0 | Sale to Issuer | |
Nov 15, 2024 | 14,861 | $1,055,131 | 0 | Sale to Issuer | ||
Evp, Chief Mktg/strtgy Officer
|
Nov 15, 2024 | 77,403 | $5,495,613 | 0 | Sale to Issuer | |
Chief Operating Officer
|
Nov 15, 2024 | 83,854 | $5,953,634 | 0 | Sale to Issuer | |
Chief Operating Officer
|
Nov 15, 2024 | 608 | $43,168 | 0 | Sale to Issuer | |
Chief Financial Officer
|
Nov 15, 2024 | 40,362 | $2,865,702 | 0 | Sale to Issuer | |
Nov 15, 2024 | 14,944 | $1,061,024 | 0 | Sale to Issuer | ||
Chief Executive Officer
|
Nov 15, 2024 | 292,731 | $20,783,901 | 0 | Sale to Issuer | |
Nov 15, 2024 | 19,861 | $1,410,131 | 0 | Sale to Issuer | ||
Nov 15, 2024 | 6,600 | $468,600 | 0 | Sale to Issuer | ||
Chief Commercial Officer
|
Nov 15, 2024 | 43,450 | $3,084,950 | 0 | Sale to Issuer | |
Nov 15, 2024 | 9,542 | $677,482 | 0 | Sale to Issuer |